FrancophonIA/ELRC3.0 huggingface dataset:
English: If vomiting occurs within 1 hour of taking Emtricitabine/Tenofovir disoproxil Krka d.d., another tablet should be taken.
Spanish: Si se vomita en el plazo de 1 hora después de tomar Emtricitabina/Tenofovir disoproxilo Krka d.d., se debe tomar otro comprimido.
English: ANTI-INFECTIVES Antiretrovirals Protease inhibitors
Spanish: Inhibidores de la proteasa
English: The safety of tenofovir disoproxil when co-administered with ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir and a pharmacokinetic enhancer has not been established.
Spanish: No se ha establecido la seguridad de tenofovir disoproxilo cuando se administra de forma concomitante con ledipasvir/sofosbuvir, sofosbuvir y velpatasvir o sofosbuvir/velpatasvir/voxilaprevir y un potenciador farmacocinético.
English: should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Spanish: si en la actualidad o recientemente se está administrando un medicamento nefrotóxico.
English: or, if you already have HIV, to take Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: o, si ya tiene VIH, tome Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Very common side effects (may affect more than 1 in 10 people) diarrhoea, being sick (vomiting), feeling sick (nausea) dizziness, headache rash feeling weak
Spanish: (pueden afectar a más de 1 de cada 10 personas) - diarrea, vómitos, ganas de vomitar (náuseas) - mareos, dolor de cabeza - erupción - sensación de debilidad
English: It is preferable that Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Es preferible que Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: HIV-1 infected patients receiving Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Los pacientes infectados por VIH-1 que reciban Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If you vomit less than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka d.d., take another tablet.
Spanish: Si vomita antes de que transcurra 1 hora tras haber tomado Emtricitabina/Tenofovir disoproxilo Krka d.d., tome otro comprimido.
English: It is important not to miss a dose of Emtricitabine/Tenofovir disoproxil Krka d.d..
Spanish: Es importante que no olvide una dosis de Emtricitabina/Tenofovir disoproxilo Krka d.d..
English: See section 2 "Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Ver sección 2 "Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Recommendation concerning coadministration with Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Recomendación relativa a la administración concomitante con Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Patients infected with HBV who discontinue Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: En pacientes infectados por VHB que abandonen el tratamiento con Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: In study GS-US-104-0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range
Spanish: En el estudio GS-US-104-0321, 87 pacientes con tratamiento previo infectados por VIH-1 de 12 a <
English: AUC: ↑ 142% (↑ 123 to ↑ 164) Cmax: ↑ 55% (↑ 41 to ↑ 71) Cmin: ↑ 301% (↑ 257 to ↑ 350)
Spanish: AUC: ↑ 142% (↑ 123 a ↑ 164) Cmax: ↑ 55% (↑ 41 a ↑ 71) Cmin: ↑ 301% (↑ 257 a ↑ 350)
English: contains lactose", "Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: contiene lactosa", "Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Your doctor will prescribe Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: - Su médico le prescribirá Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Do not breast-feed during treatment with Emtricitabine/Tenofovir disoproxil Krka d.d..
Spanish: - No dé el pecho a su hijo durante el tratamiento con Emtricitabina/Tenofovir disoproxilo Krka d.d..
English: AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6)
Spanish: Etinilestradiol AUC: ↓ 4% (↓ 9 to ↑ 0) Cmax: ↓ 6% (↓ 13 to ↑ 0) Cmin: ↓ 2% (↓ 9 to ↑ 6)
English: Summary of Product Characteristics and an appropriate educational brochure, as detailed below:
Spanish: para el tratamiento de la infección por VIH-1 en adolescentes o para la PrEP en adultos y adolescentes reciban un material informativo para médicos que contenga el Resumen de las Características del Producto y un folleto informativo adecuado, tal como se detalla a continuación:
English: is missed within 12 hours of the time it is usually taken, Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: en el plazo de 12 horas desde la hora habitual de administración, se debe tomar Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Other medicines and Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Otros medicamentos y Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: It is important not to stop taking Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Es importante no dejar de tomar Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Do not take Emtricitabine/Tenofovir disoproxil Krka d.d.if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6).
Spanish: tenofovir disoproxilo succinato, o a alguno de los demás componentes de este medicamento (incluidos en la sección 6).
English: If you get any side effects, talk to your doctor or pharmacist.
Spanish: → Si nota cualquiera de estos síntomas, hable con su médico.
English: Cmax: ↑ 102% (↓ 96 to ↑ 108)
Spanish: Cmax: ↑ 102% (↓ 96 to ↑ 108) Cmin: NC
English: The increased exposure of tenofovir could potentiate tenofovir associated adverse events, including renal disorders.
Spanish: El aumento de la exposición a tenofovir podría potenciar las reacciones adversas asociadas a tenofovir, incluyendo alteraciones renal.
English: for blister:
Spanish: Para blíster:
English: Consideration should be given to interrupting treatment with Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Se debe considerar la interrupción del tratamiento con Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Cmax: ↑ 34%
Spanish: AUC: ↑ 37% Cmax: ↑ 34%
English: In study GS-US-104-0321, 87 HIV 1 infected treatment-experienced patients 12 to < 18 years of age were treated with tenofovir disoproxil (n = 45) or placebo (n = 42) in combination with an optimised background regimen (OBR) for 48 weeks.
Spanish: 18 años de edad se trataron con tenofovir disoproxilo (n = 45) o placebo (n = 42) combinados con una pauta de base optimizada (PBO) durante 48 semanas.
English: Therefore Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Por tanto, Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: + Darunavir/Ritonavir (800 mg q.d./100 mg q.d.)
Spanish: Ledipasvir/Sofosbuvir (90 mg/400 mg c/24 h) + Darunavir/Ritonavir (800 mg q.d./100 mg q.d.)
English: How to take Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Cómo tomar Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If you take more Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Si toma más Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Interrupting treatment with Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: El abandono del tratamiento con Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Didanosine: The co-administration of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Didanosina: No se recomienda la administración concomitante de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Didanosine/Tenofovir disoproxil
Spanish: emtricitabina/tenofovir disoproxilo
English: Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: + Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.)
Spanish: + Emtricitabina/Tenofovir disoproxilo (200 mg/245 mg c/24 h)
English: Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients.
Spanish: En ausencia de ésta no se considera que esté causalmente asociada a tenofovir disoproxilo Cuando se administró emtricitabina a pacientes pediátricos, fue frecuente la anemia y fueron muy frecuentes las alteraciones de coloración de la piel (hiperpigmentación).
English: While taking Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Mientras usted esté tomando Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Renal impairment: As Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Insuficiencia renal: Dado que Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Each tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to
Spanish: Cada comprimido recubierto con película contiene 200 mg de emtricitabina y 245 mg de tenofovir disoproxilo (equivalente a 300,7 mg de tenofovir disoproxilo succinato ó 136 mg de tenofovir).
English: - Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: - Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If you have taken Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Si ha estado tomando Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: + Emtricitabine/Rilpivirine/ Tenofovir disoproxil (200 mg/25 mg/245 mg q.d.)
Spanish: Emtricitabina/Rilpivirine/ Tenofovir disoproxilo (200 mg/25 mg/245 mg c/24 h)
English: As Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Toma de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: → Do not stop taking Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: → No interrumpa el tratamiento con Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: The recommended dose of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: La dosis recomendada de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Therefore the use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Por tanto, cuando se utiliza Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If a dose of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Si se omite una dosis de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If vomiting occurs more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Si se vomita más de 1 hora después de tomar Emtricitabina/Tenofovir disoproxilo Krka d.d., no se debe tomar una segunda dosis.
English: If you forget to take Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Si olvidó una dosis de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Discontinuation of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Conservación de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: If Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Dado que Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: is not recommended for use in paediatric patients with renal impairment - That use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: en pacientes pediátricos con insuficiencia renal - Que se debe evitar el uso de Emtricitabina/Tenofovir disoproxilo Krka d.d.con el uso concomitante o reciente de medicamentos nefrotóxicos.
English: The use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: El uso de Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Increased plasma concentrations of tenofovir resulting from co administration of tenofovir disoproxil, sofosbuvir/velpatasvir and lopinavir/ritonavir may increase adverse reactions related to tenofovir disoproxil, including renal disorders.
Spanish: El aumento de las concentraciones plasmáticas de tenofovir resultante de la administración concomitante de tenofovir disoproxilo, sofosbuvir/velpatasvir y lopinavir/ritonavir puede aumentar las reacciones adversas relacionadas con tenofovir disoproxilo, incluidos los
English: What Emtricitabine/Tenofovir disoproxil Krka d.d.
Spanish: Qué es Emtricitabina/Tenofovir disoproxilo Krka d.d.
English: Signs of osteonecrosis are: joint stiffness joint aches and pains (especially of the hip, knee and shoulder) difficulty with movement → If you notice any of these symptoms tell your doctor.
Spanish: rigidez articular molestias o dolor articular (especialmente en cadera, rodilla y hombro)
English: rash
Spanish: Frasco
English: Common side effects (may affect up to 1 in 10 people) pain, stomach pain difficulty sleeping, abnormal dreams problems with digestion resulting in discomfort after meals, feeling bloated, flatulence rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches other allergic reactions, such as wheezing, swelling or feeling light-headed
Spanish: que pueden ser reacciones alérgicas, picazón, cambios en el color de la piel como oscurecimiento de la piel en parches - otras reacciones alérgicas, tales como respirar con dificultad, hinchazón o sentirse ligeramente mareado
English: • The Committee considered the notification under Article 20 of Regulation (EC) No 726/2004 for
Spanish: • El Comité valoró la notificación de acuerdo con el Artículo 20 del Reglamento (CE) Nº 726/2004
English: Scientific conclusions and grounds for the suspension of the marketing authorisation presented by the European Medicines Agency
Spanish: Conclusiones científicas y fundamentos para la suspensión de la autorización de comercialización presentada por la Agencia Europea de Medicamentos
English: MACI and the draft CHMP opinion prepared by the CAT
Spanish: para MACI y el borrador del dictamen del CHMP elaborado por el CAT.
English: The CHMP considered that this information does not impact the safety and efficacy profile of MACI but that in the absence of an authorised manufacturing site, the requirements laid down in Article 41 of Directive 2001/83/EC are no longer met.
Spanish: El CHMP considera que esta información no afecta al perfil de seguridad y eficacia de MACI pero que, en ausencia de un centro de fabricación autorizado, ya no se cumplen los requisitos establecidos en el Artículo 41 de la Directiva 2001/83/CE.
English: On 8 September 2014, Aastrom Biosciences notified the European Medicines Agency of the withdrawal by the Danish authorities of the manufacturing licence for the manufacturing site for the active substance, finished product and batch release of MACI (matrix-applied characterised autologous cultured chondrocytes): Genzyme Biosurgery ApS, Oliefabriksvej 45, DK - 2770 Kastrup, Denmark.
Spanish: El 8 de septiembre de 2014, Aastrom Biosciences notificó a la Agencia Europea de Medicamentos la retirada por parte de las autoridades danesas de la licencia de fabricación del principio activo, el producto terminado y la liberación de lotes de MACI (condrocitos autólogos cultivados y caracterizados aplicados a una matriz) otorgada al centro de fabricación: Genzyme Biosurgery ApS, Oliefabriksvej 45, DK - 2770 Kastrup, Dinamarca.
English: In view of the above, the European Commission initiated a procedure under Article 20 of Regulation (EC) No 726/2004 on 10 September 2014, requesting the Agency to give its opinion on whether the marketing authorisation for MACI should be suspended or revoked in accordance with Article 118 of
Spanish: A la vista de lo anterior, el 10 de septiembre de 2014 la Comisión Europea inició un procedimiento conforme al Artículo 20 del Reglamento (CE) Nº 726/2004, solicitando a la Agencia que emitiera un dictamen acerca de si la autorización de comercialización de MACI debería suspenderse o revocarse según el Artículo 118 de la Directiva 2001/83/CE.
English: Grounds for the suspension of the marketing authorisation
Spanish: Fundamentos para la suspensión de la autorización de
English: For the suspension of the marketing authorisation to be lifted, the MAH shall register a site for manufacture of the active substance, finished product and batch release.
Spanish: Para que se levante la suspensión de la autorización de comercialización, el TAC deberá registrar un centro para la fabricación del principio activo, el producto terminado y la liberación de los lotes.
English: For the suspension to be lifted, the MAH shall register a manufacturing site for the active substance, finished product and batch release (see Annex II).
Spanish: Para que se levante la suspensión, el TAC deberá registrar un centro de fabricación para el principio activo, el producto terminado y la liberación de lotes (véase el Anexo II).
English: • The Committee concluded that in view of the absence of an authorised manufacturing site for the active substance, finished product and batch release, the requirements laid down in Article 41 of
Spanish: • El Comité concluyó que, ante la ausencia de un centro de fabricación autorizado para el principio activo, el producto terminado y la liberación de los lotes, ya no se cumplían los requisitos establecidos en el Artículo 41 de la Directiva 2001/83/CE.
English: ATC vet code: QI07AB01.
Spanish: Código ATC vet: QI07AB01.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/14/171/001
Spanish: NÚMERO(S) DE LA AUTORIZACIÓN DE COMERCIALIZACIÓN EU/2/14/171/001
English: Once broached, use immediately.
Spanish: Una vez abierto, uso inmediato.
English: Type I glass vial containing 1 ml closed with a chlorobutyl rubber stopper and aluminium cap.
Spanish: Vial de vidrio Tipo I que contiene 1 ml, cerrado con un tapón de goma de clorobutilo y una cápsula de aluminio.
English: Pharmacotherapeutic group: Immunologicals for canidae, inactivated bacterial vaccines.
Spanish: Grupo farmacoterapéutico: inmunológicos para perros, vacunas bacterianas inactivadas.
English: Overdose (symptoms, emergency procedures, antidotes): No data are available on the safety of an overdose.
Spanish: Sobredosificación (síntomas, medidas de urgencia, antídotos): No se dispone de datos de seguridad tras una sobredosificación.
English: Onset of immunity: 4 weeks after completion of the primary course.
Spanish: Establecimiento de inmunidad: 4 semanas después de completarse el programa de primovacunación.
English: No data are available on the safety of an overdose.
Spanish: No se dispone de datos de seguridad tras una sobredosificación.
English: Active immunisation of dogs from 6 weeks of age:
Spanish: INDICACIÓN(ES) DE USO Para la inmunización activa de perros a partir de 6 semanas de edad:
English: 10 DATE OF REVISION OF THE TEXT Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Spanish: FECHA DE LA REVISIÓN DEL TEXTO Encontrará información detallada sobre este medicamento veterinario en la página web de la Agencia Europea de Medicamentos (http://www.ema.europa.eu/).
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products except those mentioned in section 4.8.
Spanish: En ausencia de estudios de compatibilidad, este medicamento veterinario no debe mezclarse con otros medicamentos veterinarios, excepto con los mencionados en la sección 4.8.
English: Dose and route of administration: Shake well and administer immediately the entire contents (1 ml) of the product.
Spanish: Posología y vía de administración: Agitar bien e inyectar inmediatamente la totalidad del contenido del medicamento (1 ml).
English: * Antibody micro agglutination-lytic reaction.
Spanish: * Microaglutinación de anticuerpos-reacción lítica.
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products other than those mentioned in section 8.
Spanish: En ausencia de estudios de compatibilidad, este medicamento veterinario no debe mezclarse con otros medicamentos veterinarios, excepto con los mencionados en la sección 8.
English: ADVICE ON CORRECT ADMINISTRATION Shake well and administer immediately the entire contents (1 ml) of the product.
Spanish: INSTRUCCIONES PARA UNA CORRECTA ADMINISTRACIÓN Agitar bien e inyectar inmediatamente la totalidad del contenido del medicamento (1 ml).
English: Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injections
Spanish: Dihidrógenofosfato de potasio Fosfato de disodio dodecahidrato Agua para preparaciones inyectables
English: Primary vaccination scheme: Two doses of Versican Plus L4 3-4 weeks apart from 6 weeks of age.
Spanish: Primovacunación: Dos dosis de Versican Plus L4 con un intervalo de 3 a 4 semanas a partir de las 6 semanas de edad.
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND
Spanish: A. FABRICANTE DE LA SUSTANCIA ACTIVA BIOLÓGICAS Y FABRICANTE
English: Duration of immunity: At least one year following the primary vaccination course for all components of Versican Plus L4.
Spanish: Al menos un año tras el programa de primovacunación para todos los componentes de Versican Plus L4.
English: The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae.
Spanish: La vacuna está indicada para la inmunización activa de perros y cachorros sanos frente a las enfermedades producidas por Leptospira interrogans serogrupo Australis serovar Bratislava, Leptospira interrogans serogrupo Canicola serovar Canicola, Leptospira kirschneri serogrupo Grippohyphosa serovar Grippohyphosa y Leptospira interrogans serogrupo Icterohaemorrhagiae serovar Icterohaemorrhagiae.
English: Appearance: whitish liquid with fine sediment.
Spanish: Apariencia: líquido de color blanquecino con un sedimento fino.
English: Plastic box containing 50 vials (1 ml).
Spanish: Caja de plástico con 50 viales (1 ml).
English: Plastic box containing 25 vials (1 ml).
Spanish: Caja de plástico con 25 viales (1 ml).
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
Spanish: La frecuencia de las reacciones adversas se debe clasificar conforme a los siguientes grupos: - Muy frecuentemente (más de 1 animal por cada 10 animales tratados presenta reacciones adversas) - Frecuentemente (más de 1 pero menos de 10 animales por cada 100 animales tratados) - Infrecuentemente (más de 1 pero menos de 10 animales por cada 1.000 animales tratados)
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 for dogs
Spanish: DENOMINACIÓN DEL MEDICAMENTO VETERINARIO Versican Plus L4 para perros
English: Re-vaccination scheme: A single dose of Versican Plus L4 to be given annually.
Spanish: Revacunación: Revacunación anual con una dosis de Versican Plus L4.
English: PACKAGE LEAFLET: Versican Plus L4 suspension for injection for dogs
Spanish: PROSPECTO: Versican Plus L4 suspensión inyectable para perros
English: L. interrogans serovar Icterohaemorrhagiae
Spanish: L. interrogans serovar Icterohaemorrhagiae título ARL ≥ 1:51
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 suspension for injection for dogs
Spanish: DENOMINACIÓN DEL MEDICAMENTO VETERINARIO Versican Plus L4 suspensión inyectable para perros
English: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versican Plus DHPPi and Versican Plus Pi. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Spanish: No existe información disponible sobre la seguridad y la eficacia del uso de esta vacuna con cualquier otro medicamento veterinario distinto de Versican Plus DHPPi y Versican Plus Pi.